



**Thomas Kurt Eigentler**

**Contact**

Thomas Kurt Eigentler

## Publications (11)

Wagner N, Knierim S, Luttermann F, Metzler G, Yazdi A, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler T, Forchhammer S, Flatz L. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. *J Am Acad Dermatol* 2023

Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. *Eur J Cancer* 2023; 196:113425.

Aebischer V, Abu-Ghazaleh A, Metzler G, Riedl L, Garbe C, Flatz L, Eigentler T, Forchhammer S. Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage. *Pigment Cell Melanoma Res* 2023; 36:512-521.

Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higueta L, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. *EBioMedicine* 2023; 93:104644.

Gaessler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner N, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. *J Immunother Cancer* 2023; 11

Schwenck J, Sonanini D, Seyfried D, Ehrlichmann W, Kienzle G, Reischl G, Krezer P, Wilson I, Korn R, Gonzalez-Menendez I, Quintanilla-Martinez L, Seith F, Forschner A, Eigentler T, Zender L, Röcken M, Pichler B, Flatz L, Kneilling M, la Fougere C. imaging of CD8 T cells in metastatic cancer patients: first clinical experience with simultaneous [Zr]Zr-Df-IAB22M2C PET/MRI. *Theranostics* 2023; 13:2408-2423.

Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. *J Clin Oncol* 2022; 40:3741-3749.

Pflugfelder A, Yong X, Jagirdar K, Eigentler T, Soyer H, Sturm R, Flatz L, Duffy D. Genome-Wide Association Study Suggests the Variant rs7551288\*A within the Gene Is Associated with Poor Overall Survival in Melanoma Patients. *Cancers (Basel)* 2022; 14

Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Riess O, Flatz L, Garbe C, Forschner A. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. *J Cancer Res Clin Oncol* 2022; 149:833-840.

Serna-Higueta L, Eigentler T, Garbe C, Thomas I, Seeber O, Flatz L, Leiter U, Forschner A, Amaral T, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. *Cancers (Basel)* 2021; 13

Gassenmaier M, Garbe C, Eigentler T, Doecker D, Mueller A, Kofler L, Wagner N, Scheu A, Lipp H, Forschner A. Safety of shortened infusion times for combined ipilimumab and nivolumab. *Cancer Immunol Immunother* 2017; 67:135-140.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)